We have wrapped up construction on the build-out of a 23,000 SF R&D facility for a company specializing in delivering next-generation medicines to patients. The new space consists of offices and proprietary labs used to perform protein degradation studies that will lead to therapeutic treatments for patients with life-altering, debilitating diseases.
